Innovation Ed
INVICTUS – Rivaroxaban vs VKA for rheumatic atrial fibrillation – #ESCCongress 2022
Video by PCR via YouTube
Go to Source
Aaysha Cader interviews Ganesan Karthikeyan who presented the results of INVICTUS during the ESC Congress 2022 in Barcelona: Among patients with rheumatic heart disease–associated atrial fibrillation, vitamin K antagonist therapy led to a lower rate of a composite of cardiovascular events or death than rivaroxaban therapy, without a higher rate of bleeding.
More news on the ESC Congress 2022 Interventional cardiology perspective on PCRonline: https://www.pcronline.com/News/Whats-new-on-PCRonline/2022/ESC-2022/PCRonline-ESC-Congress-2022